Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Veracyte is a promising company with a strong presence in the cancer diagnostics industry. Their unique GRID technology sets them apart from competitors and allows for partnerships and research opportunities. With a solid financial position, the company is not only expanding their product portfolio but also making strides towards improving patient outcomes with their MRD and chemotherapy reducing tests.

Bears say

Veracyte is a molecular diagnostics company that has experienced strong revenue growth, but remains highly dependent on just two flagship assets. Although they have recently launched two new products, there are concerns about market saturation in the thyroid testing market and slow adoption of their tests by tenured community urologists. There is potential upside with their new whole-genome MRD test and re-launch of a high-margin breast cancer test, but these may not significantly impact revenue in the near term. Additionally, the company faces competition from larger molecular diagnostics companies and potential pricing pressures.

Veracyte (VCYT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 9 analysts, Veracyte (VCYT) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.